Literature DB >> 9456284

Different effects of class Ic and III antiarrhythmic drugs on vagotonic atrial fibrillation in the canine heart.

H Hayashi1, A Fujiki, M Tani, M Usui, H Inoue.   

Abstract

Effects of class Ic drug pilsicainide and class III drug MS-551 were determined in the canine model of atrial fibrillation (AF) induced under vagal stimulation. Pilsicainide injected intravenously at a dose of 1.0 mg/kg over 3 min terminated AF in six of six dogs. After pilsicainide injection, the effective refractory period (ERP) of the right atrium (RA) increased (104 +/- 22 to 122 +/- 31 ms; p < 0.05), and intraatrial conduction time (CT) increased (24%; p < 0.05) in the RA during vagal stimulation. Wavelength index (WLI; ERP/CT), an estimate of the wavelength for reentry, was decreased slightly but significantly (-2%; p < 0.05) in the RA after pilsicainide. MS-551 injected intravenously at a dose of 0.5 mg/kg over a 3-min period terminated AF in three of eight dogs. An additional dose of 0.5 mg/kg of MS-551 terminated AF in three of the remaining five dogs. After MS-551 injection, ERP increased (100 +/- 30 to 143 +/- 28 ms; p < 0.05), but CT remained unchanged in the RA, and therefore WLI was increased significantly (48%; p < 0.01). Immediately before termination of AF with test drugs, mean AF intervals (FF intervals) increased, whereas the standard deviation of FF intervals did not change significantly. In conclusion, both pilsicainide and MS-551 effectively terminated vagotonic AF after an increase in FF intervals. However, changes in WLI were different between the two test drugs. Vagotonic AF could, therefore, be terminated either by prolongation of ERP or suppression of conduction with antiarrhythmic drugs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9456284     DOI: 10.1097/00005344-199801000-00015

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

Review 1.  Translational research in atrial fibrillation: a quest for mechanistically based diagnosis and therapy.

Authors:  Felipe Atienza; Raphael P Martins; José Jalife
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-09-27

2.  Linear lesion radiofrequency ablation in canine vagal atrial fibrillation: effects of special catheters designed for efficiency, and the critical role of lesions from the crista terminalis to the superior vena cava.

Authors:  J D Fisher; S Kahn; J Han; A Kogan; M Nanna
Journal:  J Interv Card Electrophysiol       Date:  2001-09       Impact factor: 1.900

Review 3.  Mechanisms of termination and prevention of atrial fibrillation by drug therapy.

Authors:  A J Workman; G L Smith; A C Rankin
Journal:  Pharmacol Ther       Date:  2011-02-18       Impact factor: 12.310

4.  Drug Therapy for Vagally-Mediated Atrial Fibrillation and Sympatho-Vagal Balance in the Genesis of Atrial Fibrillation: A Review of the Current Literature.

Authors:  Pattara Rattanawong; Jakrin Kewcharoen; Komandoor S Srivathsan; Win-Kuang Shen
Journal:  J Atr Fibrillation       Date:  2020-06-30

5.  Development and Validation of a Novel Prognostic Model Predicting the Atrial Fibrillation Recurrence Risk for Persistent Atrial Fibrillation Patients Treated with Nifekalant During the First Radiofrequency Catheter Ablation.

Authors:  Youzheng Dong; Zhenyu Zhai; Bo Zhu; Shucai Xiao; Yang Chen; Anxue Hou; Pengtao Zou; Zirong Xia; Jianhua Yu; Juxiang Li
Journal:  Cardiovasc Drugs Ther       Date:  2022-06-22       Impact factor: 3.727

6.  A canine model of sustained atrial fibrillation induced by rapid atrial pacing and phenylephrine.

Authors:  Anusak Kijtawornrat; Brian M Roche; Robert L Hamlin
Journal:  Comp Med       Date:  2008-10       Impact factor: 0.982

Review 7.  Animal models of arrhythmia: classic electrophysiology to genetically modified large animals.

Authors:  Sebastian Clauss; Christina Bleyer; Dominik Schüttler; Philipp Tomsits; Simone Renner; Nikolai Klymiuk; Reza Wakili; Steffen Massberg; Eckhard Wolf; Stefan Kääb
Journal:  Nat Rev Cardiol       Date:  2019-08       Impact factor: 32.419

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.